Quote:as much as i'm not a fan of GEVO's mgmt .. i'm always glad to see NR (non retail) obliterated due to years of abusive tactics' actually catching up with them ..
reminder link for reg sho (imo GEVO will be on for months) ..
well not exactly *months* with Friday's 8K being filed by GEVO's mgmt (who imo always leave a sour taste behind) .. past is prologue with GEVO .. happy to have traded (sold) a % of my *core* @ 20.55 and 24.00 this month ..
imo GEVO's mgmt never fails in creating *traders* out of *investors* ..
because of their very specific actions .. reminder reg sho triggered
and *abusive* short squeeze in play for 2 days .. post R/S and mgmt's news
re-shorting cycle was well established on the take down .. and then GEVO's 8K filed AH's Friday ..
this week GEVO's historical data
Gevo, Inc. End-of-Day Stock Quote for June 25, 2018
GEVO (Common Stock)
Last Trade: $9.98
Change: +1.55
% Change: +18.39%
Volume: 4,955,900
Day's High: 10.75
Day's Low: 8.00
Previous Close: 8.43
Exchange: NSD
Gevo, Inc. End-of-Day Stock Quote for June 26, 2018
GEVO (Common Stock)
Last Trade: $7.65
Change: -2.33
% Change: -23.35%
Volume: 6,822,600
Day's High: 8.56
Day's Low: 6.90
Previous Close: 9.98
Exchange: NSD
Gevo, Inc. End-of-Day Stock Quote for June 27, 2018
GEVO (Common Stock)
Last Trade: $7.57
Change: -0.08
% Change: -1.05%
Volume: 1,722,783
Day's High: 8.45
Day's Low: 7.42
Previous Close: 7.65
Exchange: NSD
Gevo, Inc. End-of-Day Stock Quote for June 28, 2018
GEVO (Common Stock)
Last Trade: $6.41
Change: -1.16
% Change: -15.32%
Volume: 2,262,018
Day's High: 7.45
Day's Low: 6.31
Previous Close: 7.57
Exchange: NSD
Gevo, Inc. End-of-Day Stock Quote for June 29, 2018
GEVO (Common Stock)
Last Trade: $3.80
Change: -2.61
% Change: -40.72%
Volume: 9,512,368
Day's High: 5.50
Day's Low: 3.80
Previous Close: 6.41
Exchange: NSD
GEVO's mgmt filed this on Friday .. (color/bolding emphasis is my add)
http://ir.gevo.com/phoenix.zhtml?c=238618&...;ListAll=1
Item 1.01. Entry into a Material Definitive Agreement.
On June 28, 2018, Gevo, Inc. (the “Company”) entered into an amendment (the “Third Amendment”) to the At-The-Market Offering Agreement, dated February 13, 2018, as amended on June 20, 2018 (the “First Amendment”) and June 25, 2018 (the “Second Amendment”) (as amended, the “Sales Agreement”), with H.C. Wainwright & Co., LLC (the “Agent”), which provides for the sale and issuance from time to time of common stock of the Company in an “at-the-market” offering (the “ATM Offering”). The Third Amendment, among other things, provides for an increase in the amount of common stock for issuance and sale under the ATM Offering by up to an additional $66,900,000 of shares of common stock (the “Shares”). The previous Sales Agreement provided for the sale and issuance of up to $22,995,000 of shares of common stock in the ATM Offering. To date, the Company has issued 2,920,781 shares of common stock under the ATM Offering for gross proceeds of approximately $22.9 million, including 2,915,573 shares of common stock for gross proceeds of approximately $22.9 million since March 31, 2018.
The Shares have been registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-211370), declared effective by the Securities and Exchange Commission (the “Commission”) on August 2, 2016 (the “Registration Statement”), and a prospectus, which consists of a base prospectus filed with the Registration Statement, and a prospectus supplement, dated June 28, 2018. Sales of the Shares, if any, may be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or through the Nasdaq Capital Market or any other existing trading market for the Shares, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law. If the Company and the Agent agree on any method of distribution other than sales of shares of the Company’s common stock into the Nasdaq Capital Market or another existing trading market in the United States at market prices, the Company will file a further prospectus supplement providing all information about such offering as required by Rule 424(b) under the Securities Act.
The Company intends to use the net proceeds from this offering to fund working capital and for other general corporate purposes, which may include the repayment of outstanding indebtedness.
The Sales Agreement contains customary representations, warranties and agreements by the Company, including obligations of the Company to indemnify the Agent for certain liabilities under the Securities Act. Under the terms of the Sales Agreement, the Company will pay the Agent a commission of 2.5% of the gross proceeds from sales of the Shares.
This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the Company’s common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
The foregoing description of the Sales Agreement, the First Amendment, the Second Amendment and the Third Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, the First Amendment, the Second Amendment and the Third Amendment, copies of which are incorporated by reference or filed herewith as Exhibits 1.1, 1.2, 1.3 and 1.4, and are incorporated herein by reference. A legal opinion relating to the Shares is filed herewith as Exhibit 5.1.
Item 7.01. Regulation FD Disclosure.
As of June 28, 2018, the Company had cash and cash equivalents of approximately $27.3 million.
This amount is unaudited and preliminary, and does not present all information necessary for an understanding of the Company’s financial condition as of June 28, 2018. The Company’s estimate is based solely on information available to it as of June 28, 2018. Actual results for the quarter ending June 30, 2018 remain subject to the completion of management’s and the Company’s audit committee’s final reviews and the Company’s other financial closing procedures and the completion of the preparation of the Company’s unaudited consolidated financial statements.
================
now GEVO triggered reg sho on 6.12.18 and remains there as of Friday .. 6.29.18
Trade Date Download Link File Creation Timestamp
Friday, June 29, 2018
Download
6/29/2018 11:00:23 PM
Threshold Security List
Symbol Security Name Market Category Reg SHO Threshold Flag Rule 3210
ABIL ABILITY INC SHS NEW (CYM) S Y N
ACHV ACHIEVE LIFE SCIENCE INC COM N S Y N
BLNKW BLINK CHARGING CO WT EXP 02/12 S Y N
CLBS CALADRIUS BIOSCIENCES INC COM S Y N
CTRV CONTRAVIR PHARMACEUTICALS INC S Y N
DSLV VELOCITYSHS 3X INVERSE SILVER G Y N
GEVO GEVO INC COM PAR $.01 NEW S Y N
HX HEXINDAI INC ADR (CYM) G Y N
HYND WISDOMTREE TRST NEG DURATION H G Y N
INPX INPIXON COMMON STOCK (NV) S Y N
LEDS SEMILEDS CORP COM NEW (DE) S Y N
MYSZ MY SIZE INC COM S Y N
NVIV INVIVO THERAPEUTICS HOLDINGS C S Y N
RSLS RESHAPE LIFESCIENCES INC COM N S Y N
SBOT STELLAR BIOTECHNOLOGIES INC CO S Y N
SFIX STITCH FIX INC CL A Q Y N
SRTS SENSUS HEALTHCARE INC COM S Y N
TPIV TAPIMMUNE INC COM PAR $0.001 N S Y N
TUR ISHARES MSCI TURKEY ETF G Y N
USOI CREDIT SUISSE AG NASSAU BRH X G Y N
VTVT VTV THERAPEUTICS INC CL A (DE) G Y N
XTLB XTL BIOPHARMACEUTICALS LTD. AM S Y N
http://www.nasdaqtrader.com/trader.aspx?id=RegSHOThreshold
one pattern that is crystal clear .. is that NR will continue their rinse/repeat/re-short of GEVO .. and *imo* GEVO's mgmt will accede to NR every time .. to say nothing of of awarding themselves *shares* @ every turn ..
how many months b4 GEVO's next R/S .. rhetorical ..
know the game .. work off their *efforts* .. and while i'll never say never .. odds are that the next take up on GEVO .. my *core* goes *poof* ..
4kids
